Clinical Overview

Medically Supervised Weight Management

Obesity is a complex, chronic disease — not a lifestyle choice. It is driven by powerful hormonal, genetic and neurological signals that override willpower. GLP-1 receptor agonists (such as semaglutide and tirzepatide) work with your biology, not against it, by modulating the hormones that control hunger, satiety and blood glucose.

22.5%

Average body weight lost with Mounjaro® (72 weeks, SURMOUNT-1 trial)

20.7%

Average body weight lost with Wegovy® (72 weeks, STEP 1 trial)

64%

Patients achieve ≥15% weight loss on tirzepatide 15mg

1 in 4

UK adults currently living with obesity (BMI ≥30)

NHS

NICE TA875 (2023) recommends tirzepatide (Mounjaro®) for adults with BMI ≥35, or ≥30 with weight-related comorbidities, as part of a specialist weight management service. All remote prescribing follows NPA (National Pharmacy Association) Pharmacist Independent Prescriber Guidance, including photo-based physical assessment.

Clinical data last updated18 Nov 2026 · 14:33

Your prescriber chooses the right medicine for you

Following GPhC guidance for online pharmacies, you’ll be assessed for your condition — not a specific medicine. A GPhC-registered prescriber reviews your assessment and selects the treatment that is clinically appropriate and safe for you. For high-risk medicines they will independently verify your information and, where required, arrange a two-way consultation before supplying anything.

Rx

Ready to begin your assessment?

Your answers will be reviewed by a GPhC-registered pharmacist prescriber. Results typically within 2 hours.